Retina/Vitreous News

The FDA approved Ocugen’s expanded access program for the treatment of retinitis pigmentosa with OCU400, according to a press release.

Wearing gloves for intravitreal injections does not decrease the risk for endophthalmitis but does take up time and has a significant carbon footprint, according to a study.

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses data from the DAVIO 2 trial investigating EYP-1901 for the treatment of wet age-related macular degeneration.

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

Defining intraoperative parameters for vitrectomy may help shed light on the complexity of a case, according to a study presented at the American Society of Retina Specialists meeting.

The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion, according to a press release from Roche.

Healio’s top video perspectives from the American Society of Retina Specialists meeting highlight faricimab in diabetic macular edema as well as an axitinib implant for wet age-related macular degeneration.

In this Healio Video Perspective from the ASRS meeting, Jordana G. Fein, MD, MS, of Retina Group of Washington discusses IOP outcomes in patients with diabetic macular edema who were treated with aflibercept 8 mg or aflibercept 2 mg.

Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.

Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases when delivered as a combination therapy vs. anti-VEGF-A monotherapies, according to a study.